Emerging evidence has linked MRI signal changes in deep nuclei of the brain with repeated
administration of gadolinium-based contrast agents. Gadolinium deposits have been …

Gadolinium-based contrast agents (GBCAs) have revolutionized MRI, enabling physicians
to obtain crucial life-saving medical information that often cannot be obtained with other …

Objective The purpose of this study was to determine whether gadolinium (Gd) is deposited
in brain and bone tissues in patients receiving only non–Group 1 agents, either macrocyclic …

In current practice, gadolinium-based contrast agents have been considered safe when
used at clinically recommended doses in patients without severe renal insufficiency. The …

In 1988, the first contrast agent specifically designed for magnetic resonance imaging (MRI),
gadopentetate dimeglumine (Magnevist®), became available for clinical use. Since then, a …

Gadolinium-based contrast agents (GBCAs) are commonly used for enhancement in MR
imaging and have long been considered safe when administered at recommended doses …

Objectives To prospectively compare in healthy rats the effect of multiple injections of
macrocyclic (gadoterate meglumine) and linear (gadodiamide) gadolinium-based contrast …

Residual or Retained Gadolinium: Practical Implications for Radiologists and Our Patients |
Radiology RSNA "skipMainNavigation" closeDrawerMenuopenDrawerMenu Home Journals All …

Gadolinium-based contrast agents (GBCAs) have transformed magnetic resonance imaging
(MRI) by facilitating the use of contrast-enhanced MRI to allow vital clinical diagnosis in a …

Background and purpose Gadolinium based contrast agents (GBCAs) are widely used in
magnetic resonance imaging, but recently, high signal intensity in the cerebellum structures …